Skip to main content
OpenTrials
Completed

NCT Number: NCT04383587

Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers

The purpose of this study is to identify healthcare workers with SARS CoV 2 antibodies who have not been previously diagnosed and are presumed COVID-19 negative, then determine the level of immunity in this population which could inform further decisions about widespread antibody testing in a healthcare worker population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

SARS-CoV 2 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic in Florida

Jacksonville, Florida, 32224, United States

About this study

Enrolled participants will complete a survey gauging their level of confidence they will be antibody positive. Participants will then complete serologic testing for SARS CoV 2 IgG antibodies. The study will characterize the prevalence of antibody positivity in this population and assess whether there is a correlation between a pre-test confidence level using a Likert scale and actual antibody positivity.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old.
  • Mayo Clinic employee in procedural and surgical area.
  • Suspected COVID-19 exposure.
  • Completed PCR test twice with negative results.

Exclusion criteria

  • Refusal to participate in this study.

Treatment and study plan

Serologic testing

Other

COVID19 IgG antibody testing to be performed

Primary outcomes

  1. Number of Participants With COVID-19 Antibodies

    Time frame: 1 month

    Presence of IgG antibodies detected

Secondary outcomes

  1. Ability to Predict Immune Status/Antibody Positivity

    Time frame: Single point in time prior to COVID-19 Antibody testing

    Survey of participants to gauge their confidence they will be antibody positive

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
May 12, 2020
Registry last updated
Apr 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.